Medicine Description dextrose-haidylena 10%
Dextrose Haidylena intravenous solution is a medication that primarily serves to provide a concentrated source of carbohydrates, specifically in the form of glucose. Upon administration, dextrose is rapidly absorbed into the bloodstream, leading to an increase in blood glucose levels. This swift rise in glucose concentration is pivotal for patients who are unable to consume food orally, as it ensures a continuous supply of energy for cellular metabolism. Moreover, the infusion of dextrose can promote osmotic diuresis, aiding in fluid balance by drawing water into the vascular space. This mechanism is particularly beneficial in clinical scenarios where rapid energy replenishment is essential, such as in cases of hypoglycemia or during postoperative recovery.
Indications and Uses of Dextrose Haidylena intravenous solution
- Management of hypoglycemia
- Replenishment of fluids and calories in patients unable to eat
- Supportive care during and after surgical procedures
- Rehydration in instances of dehydration resulting from fever, vomiting, or diarrhea
- Maintenance of energy supply in critical care settings
Side Effects of Dextrose Haidylena intravenous solution
- Hyperglycemia
- Fluid overload
- Electrolyte imbalances
- Phlebitis at the injection site
- Allergic reactions
Storage and Handling
Store Dextrose Haidylena intravenous solution at room temperature, away from direct sunlight and moisture. Ensure that the solution is kept in a secure, sterile environment. Do not freeze the product, and check for particulate matter or discoloration before use.
Patient Advice and Precautions
Always monitor blood glucose levels during treatment, especially in patients with diabetes or those at risk for hyperglycemia. Educate patients and caregivers about the signs of potential side effects, including symptoms of hyperglycemia. Ensure that intravenous access is maintained properly to prevent complications such as phlebitis. Be cautious when administering to patients with renal impairment or those receiving concurrent fluid therapy.